| 摘要: |
| ［摘要］ 目的 探讨癌-睾丸抗原NY-SAR-35在结直肠癌（CRC）组织中的表达情况及其临床意义。方法 选择2009年10月至2012年5月于广西医科大学第一附属医院普外科接受手术治疗的CRC患者59例。男42例，女17例；年龄30～86（55.55±14.36）岁；TNM分期为Ⅰ～Ⅱ期38例，Ⅲ～Ⅳ期21例。均经手术取癌组织及配对的癌旁组织。采用逆转录聚合酶链反应（RT-PCR）检测组织NY-SAR-35 mRNA的表达情况。分析CRC组织NY-SAR-35 mRNA表达情况与患者临床特征及预后的关联性。结果 CRC组织中NY-SAR-35 mRNA阳性表达率显著高于癌旁组织（35.59% vs 13.56%，P<0.05）。CRC组织NY-SAR-35 mRNA阳性组肿瘤直径≥5 cm的人数比例显著大于阴性组（P<0.05），但两组在性别、年龄、肿瘤位置、癌胚抗原（CEA）水平、T分期、N分期、M分期、TNM分期、组织学类型和分化程度方面比较差异无统计学意义（P>0.05）。NY-SAR-35 mRNA阴性组的生存预后优于阳性组（生存期：57.24个月 vs 40.71个月；log-rank检验： χ2=4.356，P=0.037）。Cox回归分析结果显示，T分期为T3～4期、N分期为N1～3期、M分期为M1期以及NY-SAR-35 mRNA阳性表达是影响CRC患者生存预后的独立危险因素（P<0.05）。结论 NY-SAR-35 mRNA在CRC组织中高表达，且与患者不良预后具有相关性，具有作为CRC治疗靶点的潜在价值。 |
| 关键词: 结直肠癌 癌-睾丸抗原 NY-SAR-35 预后 |
| DOI：10.3969/j.issn.1674-3806.2022.07.08 |
| 分类号:R 735.3 |
| 基金项目:国家自然科学基金项目（编号：81960453，81860445）；广西自然科学基金项目（编号：2018GXNSFAA050058）；广西区域性高发肿瘤早期防治研究教育部重点实验室课题项目（编号：GEK2019-08，GKE-ZZ202006） |
|
| Expression of cancer-testis antigen NY-SAR-35 in colorectal cancer tissues and its clinical significance |
|
WANG Yan-jing, SHEN Ning, LUO Bin, et al.
|
|
Department of Histology and Embryology, School of Basic Medical Sciences, Guangxi Medical University, Nanning 530021, China
|
| Abstract: |
| ［Abstract］ Objective To investigate the expression of cancer-testis antigen NY-SAR-35 in colorectal cancer(CRC) tissues and its clinical significance. Methods Fifty-nine patients with CRC who received surgical treatment in Department of General Surgery, the First Affiliated Hospital of Guangxi Medical University from October 2009 to May 2012 were selected. Among the patients, there were 42 males and 17 females, and the age of the patients ranged from 30 to 86 years, with an average age of (55.55±14.36)years; 38 cases were in TNM stage Ⅰ-Ⅱ, and 21 cases in TNM stage Ⅲ-Ⅳ. The cancer tissues and matched paracancerous tissues were obtained by surgery. Reverse transcription-polymerase chain reaction(RT-PCR) was used to detect the expression of NY-SAR-35 mRNA in the tissues. The correlation between the expression of NY-SAR-35 mRNA in the CRC tissues and the clinical characteristics and prognosis of the patients was analyzed. Results The positive expression rate of NY-SAR-35 mRNA in the CRC tissues was significantly higher than that in the paracancerous tissues(35.59% vs 13.56%, P<0.05). The proportion of the patients with tumor diameter ≥5 cm in the NY-SAR-35 mRNA positive group in the CRC tissues was significantly greater than that in the negative group(P<0.05), but there were no significant differences between the two groups in gender, age, tumor location, carcinoembryonic antigen(CEA) level, T stage, N stage, M stage, TNM stage, histological type and degree of differentiation(P>0.05). The survival prognosis of the NY-SAR-35 mRNA negative group was better than that of the NY-SAR-35 mRNA positive group(survival periods: 57.24 months vs 40.71 months; log-rank test: χ2=4.356, P=0.037). The results of Cox regression analysis showed that T3-4 of T stage, N1-3 of N stage, M1 of M stage, and the positive expression of NY-SAR-35 mRNA were the independent risk factors affecting the survival prognosis of the CRC patients(P<0.05). Conclusion NY-SAR-35 mRNA is highly expressed in CRC tissues and is associated with poor prognosis of the patients, and has potential value as a therapeutic target for CRC. |
| Key words: Colorectal cancer(CRC) Cancer-testis antigen NY-SAR-35 Prognosis |
